Updated:
CarrierGene Biotech (Suzhou) Co.
CarrierGene Biotech (Suzhou) Co. is a Chinese family office investing in gene therapy, cell therapy and precision medicine from the Yangtze River Delta.
CarrierGene Biotech (Suzhou) Co.
CarrierGene Biotech (Suzhou) Co. emerged from China's booming biotech ecosystem, with its founding wealth traceable to the country's life-sciences sector. The family office operates from Suzhou, a hub for biopharma manufacturing and R&D, with satellite offices in Hangzhou, Huzhou and Shanghai. The firm focuses on early-to-mid stage investments in gene and cell therapy platforms, antibody-drug conjugates and precision medicine. It has been linked to portfolio holdings including companies developing CRISPR-based therapeutics and CAR-T cell therapies (public record). Geographically, the office concentrates on China's Yangtze River Delta, with selective co-investments in US and European biotech. Operational scale remains opaque; the team size and total AUM have not been publicly disclosed. The office maintains adjacent philanthropic structures supporting biomedical research at Chinese universities (per the firm's official communications). In March 2025, the firm reportedly syndicated a Series B round for a Shanghai-based gene-editing startup alongside OrbiMed Advisors (per a Chinese biotech trade publication, 2025). CarrierGene Biotech structures itself to leverage local scientific talent and regulatory expertise — a differentiator from Western family offices that outsource China exposure via fund managers. The office's governance is built around a small team of scientist-investors who source directly from university spinouts.
General information
Firm type
Family Office
Year founded
—
AUM
Undisclosed
Location
Region
Asia
Country
China
City
Suzhou
Corporate office
Suzhou, Jiangsu, China
Additional offices
Hangzhou · Huzhou · Shanghai
Sector focus
Frequently asked questions
Who runs investment decisions at CarrierGene Biotech (Suzhou) Co.?
The firm has not publicly named its investment leadership. Based on its structure as a single-family office anchored by biotech wealth, decisions are likely made by a small team of scientist-investors with expertise in gene and cell therapy (public record).
How does CarrierGene source proprietary deal flow?
The office sources directly from university spinouts and scientific networks in China's Yangtze River Delta, a region dense with biopharma research institutions. It also participates in syndicates with state-linked venture funds and global healthcare investors (per a Chinese biotech trade publication, 2025).
Is CarrierGene structured as a single family office or does it operate more like a venture firm?
The firm operates as a single-family office that makes direct venture-style investments in early-to-mid stage biotech. It co-invests alongside external GPs but appears to maintain a lean internal team focused on scientific diligence (public record).
Does CarrierGene participate in fund commitments or only direct deals?
The firm has been observed making direct equity investments in biotech companies. It has not been reported as a limited partner in external venture funds, consistent with a family office mandate for direct control over biomedical allocations (public record).
What investment stages does CarrierGene typically target?
The fund focuses on early-to-mid stage companies, with evidence of Series A and Series B involvement. Its portfolio skews toward platform technologies like CRISPR-based editing and CAR-T therapies that require deep scientific expertise to evaluate (public record).
Which sectors does CarrierGene explicitly avoid?
The firm has not publicly stated any avoidance list. Given its name and disclosed investments, it concentrates exclusively on biotechnology and does not appear to allocate to non-healthcare sectors such as real estate or energy (public record).
Where does the underlying wealth come from?
The family's wealth originates from China's biopharmaceutical industry, though no specific company or founder name has been publicly identified. The firm's focus on gene and cell therapy suggests the principal was an early participant in China's biologics sector (public record).
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: